Compare Smith & Nephew plc (SNN) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Tilray Brands Inc — how do they compare? Smith & Nephew plc trades at $27.24 (market cap $11.10B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: Smith & Nephew plc is far larger — about 20.9× Tilray Brands Inc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 121 Days and Tilray Brands Inc for 31 Days on average.
| SNN | TLRY | |
|---|---|---|
Market Cap | $11.10B | $530.54M |
Volume | 1,051,703 | 9,099,075 |
Sector | Health | Health |
52-Week High | $37.17 | $17.20 |
52-Week Low | $26.42 | $3.54 |
Typical Hold Time | 121 Days | 31 Days |
Enterprise Value | $14.13B | $684.46M |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Tilray Brands (TLRY) trades at $3.59, down 3.36% on the day and near 52-week lows, with bearish technical indicators dominating. The company reported $821 million in revenue for 2025 but posted a massive $2.19 billion net loss due to impairment charges. Recent earnings have consistently missed expectations, though analyst consensus remains cautiously optimistic with a $65.01 price target. The stock faces significant headwinds from ongoing profitability challenges and cannabis industry volatility.
TLRY presents a high-risk opportunity with potential upside if management can achieve profitability and capitalize on cannabis reform catalysts. However, persistent losses, negative cash flow, and competitive pressures create substantial downside risk. Investors should weigh the speculative nature against potential regulatory catalysts in the coming months.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
